Finasteride in Preventing the Recurrence of Prostate Cancer
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Finasteride (Proscar) for the Chemoprevention of Prostate Cancer
Basic Trial Information
|Phase III||Prevention||Completed||55 and over||NCI||SWOG-9217|
Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether finasteride is effective in preventing the recurrence of prostate cancer.
- At least 55 years old
- No previous finasteride
- No previous chemotherapy, hormone therapy, or radiation therapy
- At least 6 months since transurethral resection of the prostate
- For more information about the eligibility criteria for this trial, refer to the Health Professional version.
Final eligibility for a clinical trial is determined by the health professionals conducting the trial.
Patients will be randomly assigned to one of two groups. Patients in group one will receive finasteride. Patients in group two will receive a placebo.
For more details about this trial, refer to the Health Professional version of the trial summary.
If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.
Trial Contact Information
Trial Lead Organizations
Southwest Oncology Group